4Degrees is a relationship intelligence and deal flow platform designed for relationship-driven teams in private equity, venture capital, and commercial real estate. The platform automates workflows, eliminates manual data entry, and provides insights into relationship networks, enabling users to discover new opportunities and manage deals more efficiently. With features like relationship strength scoring and integration with existing tools, 4Degrees helps firms save time and enhance collaboration, making it a valuable asset for organizations looking to leverage their networks for successful deal-making.

Acesion Pharma Ap S is a Danish biotech company founded in 2011, focused on developing more efficacious and safer drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The company utilizes a novel approach by inhibiting the SK ion channel, aiming to create first-in-class therapies that address the significant patient need for better treatment options. With a strong foundation in research from the University of Copenhagen and insights from Neurosearch, Acesion Pharma is positioned to make a substantial impact in the cardiology market, particularly as existing therapies have limited effectiveness and carry risks of serious adverse events. The company has demonstrated traction through positive clinical results and significant financing rounds, indicating strong investor confidence and potential for growth in the biotech sector.

Actio Biosciences is a precision medicine company focused on developing life-changing treatments that target shared biology between rare and common diseases. By leveraging advances in genetics and drug discovery, they aim to enhance the probability of clinical success by starting with rare diseases, where they can pinpoint specific genetic targets. This unique approach not only addresses high unmet needs in rare diseases but also guides therapeutic expansion into more prevalent conditions, positioning Actio as a leader in genetics-led drug development.

Aer Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutic solutions for muco-obstructive lung diseases, particularly targeting conditions like COPD, cystic fibrosis, and asthma. Their lead product, AER-01, is a novel inhaled mucolytic agent designed to effectively liquefy mucus plugs, addressing a significant unmet medical need in patients suffering from airway obstruction. The company leverages advanced lung imaging techniques to identify patients with clinically silent mucus plugs and measure the efficacy of their treatments. With a strong foundation in research and development, supported by over $18M in NIH funding, Aer Therapeutics is positioned to make a substantial impact in the respiratory disease market.

Aeva is a technology company specializing in advanced sensing and perception systems for autonomous navigation. Their key products, Aeries II and Atlas, utilize innovative FMCW technology to provide 4D LiDAR sensors that detect velocity and range simultaneously, enhancing the decision-making capabilities of autonomous vehicles and robots. Aeva differentiates itself with automotive-grade sensors designed for mass production, aiming to revolutionize the autonomous mobility market. The company has secured significant contracts, including a $1 billion deal with Daimler Truck, positioning it as a leader in the autonomous sensing space.

Agomab Therapeutics is focused on developing innovative therapies to treat fibrosis and restore organ function across multiple therapeutic areas. Their pipeline includes AGMB-129, a small molecule inhibitor targeting fibrostenosing Crohn’s disease, AGMB-447 for idiopathic pulmonary fibrosis, and AGMB-101 for liver cirrhosis. The company differentiates itself through its expertise in growth factor biology and a commitment to biologically validated pathways, positioning itself strongly in the biopharmaceutical market. With a recent $89 million Series D financing, Agomab is well-equipped to advance its clinical development and expand its impact in treating fibrotic diseases.

Aim Security specializes in providing comprehensive security solutions for enterprises adopting generative artificial intelligence (AI). The company's platform is designed to address the unique security challenges posed by AI, including data exposure, supply chain vulnerabilities, and malicious outputs. Aim's offerings include AI-SPM and AI-Firewall, which help organizations secure their AI usage and mitigate risks in real-time. With a focus on compliance and data protection, Aim positions itself as a leader in the rapidly evolving AI security market, catering to enterprises looking to leverage AI safely and effectively.

Aireye is a next-generation Wi-Fi firewall platform that serves as a critical first line of defense for wireless security. It offers agentless, AI-driven, and SaaS solutions that protect IT and OT assets without isolating them from the network. Aireye's unique approach allows for continuous monitoring and real-time detection of unauthorized access and data leakage, making it essential for industries like healthcare and defense. With a projected growth in Wi-Fi assets and increasing vulnerabilities, Aireye positions itself as a leader in network airspace control, ensuring the protection of critical assets against evolving threats.

Theia is a healthtech company focused on providing respectful prenatal and childbirth care, emphasizing a coordinated approach with a multidisciplinary team. They offer services from pregnancy through the first year of a child's life, ensuring that mothers have access to a range of specialists and 24/7 support. Theia differentiates itself by prioritizing patient autonomy and evidence-based information, and it has seen significant growth, including a fivefold increase in revenue in 2021 and over a thousand consultations performed. The company has established partnerships with health plans, making their services accessible to a broader audience.

Alkymi is a software company that empowers financial services firms by unlocking the full value of private markets data through AI-powered automation. Founded in 2017 by a team from Bloomberg and Two Sigma, Alkymi transforms unstructured data from various sources into actionable insights, enabling businesses to accelerate decision-making and improve operational efficiency. Their platform supports multiple investment document workflows, allowing firms to manage capital notices, financial statements, and more in a single solution. With backing from notable investors like Intel Capital and Canaan, Alkymi is positioned as a leader in the financial data operations space, helping clients respond quickly to market changes and enhance their data quality.

Almanac is a collaborative infrastructure platform designed to enhance human creativity through streamlined workflows and documentation. It offers a powerful wiki and workflow tool that enables teams to manage knowledge effectively, reduce meeting times, and improve collaboration with features like version control, approvals, and integrations with popular tools. With a focus on security and compliance, including SOC2 and HIPAA, Almanac positions itself as a trusted solution for innovative companies and distributed teams looking to enhance productivity and transparency in their operations.

Alpaca is a tech start-up that helps both renters and landlords throughout the tedious journey of renting apartments. Its team has helped over 4 million roommates, renters, and landlords through the process of finding a home. Alpaca’s AI manages the largest network of housing Facebook groups in the world, active in over 200 cities. The company was founded in 2018 and is headquartered in Berlin, Germany.